Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 126Radiotherapy 119Cisplatin 112Carboplatin 112pembrolizumab 110Nivolumab 106Docetaxel 91Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Fluorouracil 64Bevacizumab 64Oxaliplatin 63Etoposide 63Filgrastim 59Capecitabine 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 54Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡